

BLONDER TONGUE LABORATORIES INC  
Form 8-K  
April 12, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 4, 2017**

**Blonder Tongue Laboratories, Inc.**

**(Exact Name of registrant as specified in its charter)**

**Delaware**

**1-14120**

**52-1611421**

**(State or other jurisdiction of incorporation) (Commission File Number)**

**(I.R.S. Employer Identification No.)**

**One Jake Brown Road, Old Bridge, New Jersey 08857**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (732) 679-4000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 4, 2017, Blonder Tongue Laboratories, Inc. (the “Company”) granted options to purchase 40,000 shares of the Company’s common stock to Nezam Nikoo, the Company’s Vice President of Engineering and CTO pursuant to an agreement between the Company and Mr. Nikoo dated as of April 3, 2017. The per share exercise price of the options is \$0.55 (equal to the average of the high and low selling prices as reported on the NYSE MKT of the common stock on the grant date and vesting of the options is subject to performance-based vesting criteria agreed to by the Company and Mr. Nikoo.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BLONDER TONGUE LABORATORIES, INC.

By: /s/ Eric Skolnik

Eric Skolnik

Senior Vice President and Chief Financial Officer

Date: April 11, 2017